The specific process inhibited is the type I and type II interferon (interferon- (IFN-) α and IFN-γ) signaling through the Janus kinase signal transducer and activator of transcription (Jak-STAT) pathway, which supports the ability to enhance tumor recognition by the immune system and facilitate a robust T-cell response [17,18,19]. Here, IFNG is linked to neoplasm.